{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:51:55Z","timestamp":1779148315755,"version":"3.51.4"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>Our previous study demonstrated that 5-(4-hydroxy-3-dimethoxybenzylidene)-thiazolidinone (RD-1), one of rhodamine derivatives, significantly improves motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model and could minimize mitochondrial impairment, which is a potential therapeutic target to slow down the dopaminergic neurodegeneration in Parkinson\u2019s disease. To further evaluate its therapeutic and antioxidative potential in Parkinson\u2019s disease, the current study was designed to explore the effect of RD-1 on hemiparkinsonian rats following unilateral 6-hydroxydopamine lesions. Motor functional behavioral tests, including apomorphine-induced rotational analysis and beam walking tests, were assessed. Our results showed that oral RD-1 administration for 2\u2009weeks alleviated beam walking disability, but not the rotational behavior. Furthermore, compared to the sham group, tyrosine hydroxylase- (TH-) positive neurons in the substantia nigra pars compacta and fibers in the striatum were significantly preserved in the RD-1 treatment group. The abnormal activities of superoxide dismutase, catalase, and glutathione peroxidase and contents of MDA were evidently ameliorated by RD-1, at least partly. We conclude that RD-1 could improve motor functions and alleviate the loss of dopaminergic expression in the nigrostriatal pathway of Parkinson\u2019s disease rats, and the protective mechanism of RD-1 against neurodegeneration was possibly via its modulation of antioxidation.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000712","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T22:08:35Z","timestamp":1675375715000},"page":"68-77","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["5-(4-Hydroxy-3-dimethoxybenzylidene)-thiazolidinone improves motor functions and exerts antioxidant potential in hemiparkinsonian rats"],"prefix":"10.1097","volume":"34","author":[{"given":"Zhili","family":"Ren","sequence":"first","affiliation":[{"name":"Department of Neurobiology, Neurology and Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing Institute of Geriatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Neurology and Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing Institute of Geriatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Neurology and Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing Institute of Geriatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Basic Medical Sciences, Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Basic Medical Sciences, Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piu","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Neurology and Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing Institute of Geriatrics"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University"},{"name":"Laboratory for Neurodegenerative Disease of the Ministry of Education, Beijing Key Laboratory for Parkinson\u2019s Disease, Clinical Center for Parkinson\u2019s Disease, Capital Medical University"},{"name":"Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders, Capital Medical University"},{"name":"National Clinical Research Center for Geriatric Disorders"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson\u2019s disease: risk factors and prevention.","volume":"15","author":"Ascherio","year":"2016","journal-title":"Lancet Neurol"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0028-3908(89)90037-3","article-title":"Relationship between rotational behaviour induced by apomorphine and caffeine in rats with unilateral lesion of the nigrostriatal pathway.","volume":"28","author":"Casas","year":"1989","journal-title":"Neuropharmacology"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/antiox9010052","article-title":"Antioxidant therapy in Parkinson\u2019s disease: insights from drosophila melanogaster.","volume":"9","author":"De Lazzari","year":"2020","journal-title":"Antioxidants (Basel)"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1006\/exnr.2002.7891","article-title":"Modeling Parkinson\u2019s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.","volume":"175","author":"Deumens","year":"2002","journal-title":"Exp Neurol"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.4103\/1673-5374.300980","article-title":"Oxidative stress factors in Parkinson\u2019s disease.","volume":"16","author":"Dorszewska","year":"2021","journal-title":"Neural Regen Res"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3390\/antiox11020405","article-title":"CNS redox homeostasis and dysfunction in neurodegenerative diseases.","volume":"11","author":"Goldsteins","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/mds.25032","article-title":"Pathogenesis of Parkinson\u2019s disease.","volume":"28","author":"Hirsch","year":"2013","journal-title":"Mov Disord"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0006-8993(93)90576-9","article-title":"Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats.","volume":"626","author":"Hudson","year":"1993","journal-title":"Brain Res"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease.","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1078\/0940-2993-00301","article-title":"Behavioral phenotyping of mice in pharmacological and toxicological research.","volume":"55","author":"Karl","year":"2003","journal-title":"Exp Toxicol Pathol"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/jama.2015.120","article-title":"Effect of creatine monohydrate on clinical progression in patients with Parkinson disease.","volume":"313","author":"Kieburtz","year":"2015","journal-title":"JAMA"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"113342","DOI":"10.1016\/j.bbr.2021.113342","article-title":"Marijuana improved motor impairments and changes in synaptic plasticity-related molecules in the striatum in 6-OHDA-treated rats.","volume":"410","author":"Komeili","year":"2021","journal-title":"Behav Brain Res"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"948","DOI":"10.2174\/1389557516666160928162724","article-title":"A comprehensive review on the biological and pharmacological activities of rhodanine based compounds for research and development of drugs.","volume":"18","author":"Liu","year":"2018","journal-title":"Mini Rev Med Chem"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1523\/JNEUROSCI.19-04-01284.1999","article-title":"Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons.","volume":"19","author":"Lotharius","year":"1999","journal-title":"J Neurosci"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/17460441.2020.1696768","article-title":"Drug screening of rhodanine derivatives for antibacterial activity.","volume":"15","author":"Maddila","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-1-0716-1495-2_10","article-title":"Generation of mitochondrial toxin rodent models of parkinson\u2019s disease using 6-OHDA, MPTP, and rotenone.","volume":"2322","author":"Maegawa","year":"2021","journal-title":"Methods Mol Biol"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.brainres.2003.12.034","article-title":"The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro.","volume":"1004","author":"Mazzio","year":"2004","journal-title":"Brain Res"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3233\/JPD-219006","article-title":"Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2021 update.","volume":"11","author":"McFarthing","year":"2021","journal-title":"J Parkinsons Dis"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1212\/WNL.41.9.1469","article-title":"Motor initiation versus execution in normal and Parkinson\u2019s disease subjects.","volume":"41","author":"Montgomery","year":"1991","journal-title":"Neurology"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1007\/s12035-015-9392-y","article-title":"The deleterious effects of oxidative and nitrosative stress on palmitoylation, membrane lipid rafts and lipid-based cellular signalling: new drug targets in neuroimmune disorders.","volume":"53","author":"Morris","year":"2016","journal-title":"Mol Neurobiol"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1080\/21691401.2019.1573824","article-title":"A conceptual review of rhodanine: current applications of antiviral drugs, anticancer and antimicrobial activities.","volume":"47","author":"Mousavi","year":"2019","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"R23-20250614","first-page":"422","article-title":"MPTP-induced mouse model of Parkinson\u2019s disease: a promising direction of therapeutic strategies.","volume":"21","author":"Mustapha","year":"2021","journal-title":"Bosn J Basic Med Sci"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"826193","DOI":"10.3389\/fncel.2022.826193","article-title":"Evidence that substantia nigra pars compacta dopaminergic neurons are selectively vulnerable to oxidative stress because they are highly metabolically active.","volume":"16","author":"Ni","year":"2022","journal-title":"Front Cell Neurosci"},{"issue":"Suppl 1","key":"R25-20250614","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.parkreldis.2015.09.004","article-title":"Non-motor symptoms in Parkinson\u2019s disease.","volume":"22","author":"Pfeiffer","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jneumeth.2007.03.021","article-title":"A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl.","volume":"164","author":"Quinn","year":"2007","journal-title":"J Neurosci Methods"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.mcna.2018.10.014","article-title":"Parkinson\u2019s disease.","volume":"103","author":"Reich","year":"2019","journal-title":"Med Clin North Am"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.neuropharm.2015.01.030","article-title":"Neuroprotective effects of 5-(4-hydroxy-3-dimethoxybenzylidene)-thiazolidinone in MPTP induced Parkinsonism model in mice.","volume":"93","author":"Ren","year":"2015","journal-title":"Neuropharmacology"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41401-018-0077-8","article-title":"Ganoderma lucidum extract ameliorates MPTP-induced parkinsonism and protects dopaminergic neurons from oxidative stress via regulating mitochondrial function, autophagy, and apoptosis.","volume":"40","author":"Ren","year":"2019","journal-title":"Acta Pharmacol Sin"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"17","DOI":"10.33549\/physiolres.933895","article-title":"In vivo, in vitro and pharmacologic models of Parkinson\u2019s disease.","volume":"68","author":"Salari","year":"2019","journal-title":"Physiol Res"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson disease.","volume":"18","author":"Schapira","year":"2017","journal-title":"Nat Rev Neurosci"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2013.04.004","article-title":"Mitochondrial dysfunction and oxidative stress in Parkinson\u2019s disease.","volume":"106\u2013107","author":"Subramaniam","year":"2013","journal-title":"Prog Neurobiol"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.2174\/092986709788186200","article-title":"Rhodanine as a privileged scaffold in drug discovery.","volume":"16","author":"Tomasic","year":"2009","journal-title":"Curr Med Chem"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"e13031","DOI":"10.1111\/acel.13031","article-title":"Oxidative stress in the aging substantia nigra and the etiology of Parkinson\u2019s disease.","volume":"18","author":"Trist","year":"2019","journal-title":"Aging Cell"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fphar.2014.00038","article-title":"The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders.","volume":"5","author":"Urrutia","year":"2014","journal-title":"Front Pharmacol"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00702-019-02133-6","article-title":"6-Hydroxydopamine: a far from simple neurotoxin.","volume":"127","author":"Vareslija","year":"2020","journal-title":"J Neural Transm (Vienna)"},{"key":"R37-20250614","doi-asserted-by":"crossref","first-page":"112406","DOI":"10.1016\/j.biopha.2021.112406","article-title":"Review of anticancer potentials and structure-activity relationships (SAR) of rhodanine derivatives.","volume":"145","author":"Yin","year":"2022","journal-title":"Biomed Pharmacother"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:01:52Z","timestamp":1749938512000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000712","relation":{},"ISSN":["0955-8810"],"issn-type":[{"value":"0955-8810","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,30]]}}}